HDAC4 Inhibitors with Cyclic Linker and Non‐hydroxamate Zinc Binding Group: Design, Synthesis, HDAC Screening and in vitro Cytotoxicity evaluation.
- 12 July 2021
- journal article
- research article
- Published by Wiley in ChemistrySelect
- Vol. 6 (26), 6748-6763
- https://doi.org/10.1002/slct.202102061
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Histone Deacetylase (HDAC) Inhibitors with a Novel Connecting Unit Linker Region Reveal a Selectivity Profile for HDAC4 and HDAC5 with Improved Activity against Chemoresistant Cancer CellsJournal of Medicinal Chemistry, 2012
- miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eµ-miR-155 transgenic mouse modelProceedings of the National Academy of Sciences of the United States of America, 2012
- Synthesis, Characterization and Biological Evaluation of Ureidofibrate-Like Derivatives Endowed with Peroxisome Proliferator-Activated Receptor ActivityJournal of Medicinal Chemistry, 2011
- microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicityBritish Journal of Cancer, 2010
- Novel histone deacetylase inhibitors in clinical trials as anti-cancer agentsJournal of Hematology & Oncology, 2010
- PPAR and Agonists against Cancer: Rational Design of Complementation TreatmentsPPAR Research, 2008
- HDAC4 Promotes Growth of Colon Cancer Cells via Repression of p21Molecular Biology of the Cell, 2008
- Structural and Functional Analysis of the Human HDAC4 Catalytic Domain Reveals a Regulatory Structural Zinc-binding DomainOnline Journal of Public Health Informatics, 2008
- HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregatesGenes & Development, 2007
- Differential protein acetylation induced by novel histone deacetylase inhibitorsBiochemical and Biophysical Research Communications, 2004